摘要
目的:探讨趋化因子配体13(CXCL13)在肝细胞癌(HCC)组织中的表达及与临床病理特征和预后的关系。方法:利用免疫组织化学方法检测CXCL13在111例HCC患者术后癌组织和相应癌旁组织标本中的表达情况,分析HCC患者临床病理特征、预后及术后复发的相关性。结果:HCC中CXCL13的阳性表达明显高于相应癌旁组织(P<0.01),CXCL13在有血管浸润的组织中阳性表达率明显高于无血管浸润的组织(P=0.031),在TNM分期中Ⅲ+Ⅳ期的阳性表达率明显高于I+Ⅱ期(P=0.026)。单因素分析结果显示:甲胎蛋白、血管浸润、TNM分期、癌组织CXCL13表达是肝细胞癌的预后相关因素(P<0.01);多因素回归分析表明:甲胎蛋白(P=0.001)、癌组织CXCL13表达(P=0.005)是肝癌患者独立预后相关因素;Kaplan-Meier生存曲线分析结果显示:CXCL13阴性表达组总生存时间和无复发生存时间优于阳性表达组(P=0.0023、0.0085)。结论:CXCL13在HCC组织中高表达并与肿瘤的浸润性生长和TNM分期密切相关,其可作为HCC患者治疗效果和预后评估的一项重要指标。
Objective:To investigate the expression of CXCL13 in hepatocellular carcinoma(HCC)and its correlation with clinicopathological features and prognosis.Methods:Immunohistochemical method was used to detect the expression of CXCL13 in postoperative cancer tissues and corresponding paracancerous tissue specimens of 111 HCC patients,and the correlation between the clinicopathological features,prognosis and postoperative recurrence of HCC patients was analyzed.Results:The positive expression of CXCL13 in HCC was significantly higher than that in paracancerous tissues(P<0.01).The positive expression rate of CXCL13 in vascular infiltrated tissues was significantly higher than that in non-vascular infiltrated tissues(P=0.031),and the positive expression rate of stageⅢ+Ⅳin TNM stage was significantly higher than that in stageⅠ+Ⅱ(P=0.026).Univariate analysis showed that alpha-fetoprotein,vascular invasion,TNM staging,and CXCL13 expression in cancer tissues were the prognostic factors related to HCC(all P<0.01).Multivariate regression analysis showed that alpha-fetoprotein(P=0.001)and CXCL13 expression in cancer tissues(P=0.005)were independent prognostic factors in HCC patients.Kaplan-Meier survival curve analysis showed that the overall survival time and relapse-free survival time of the CXCL13 negative expression group were better than those of the positive expression group(P=0.0023,0.0085).Conclusion:The high expression of CXCL13 in HCC tissues is closely related to invasive tumor growth and TNM stage,which can be used as an important indicator for the treatment effect and prognosis of HCC patients.
作者
何海涛
王智翔
张小弟
沈乃营
张毅
HE Haitao;WANG Zhixiang;ZHANG Xiaodi;SHEN Naiying;ZHANG Yi(Xi’an Medical University,Xi’an 710068,China)
出处
《陕西医学杂志》
CAS
2021年第2期236-240,共5页
Shaanxi Medical Journal
基金
陕西省咸阳市科学技术研究发展计划项目(2019K02-108)。
关键词
趋化因子配体13
肝细胞癌
肿瘤微环境
临床病理特征
预后
复发
Chemokine ligand 13
Hepatocellular carcinoma
Tumor microenvironment
Clinicopathological feature
Prognosis
Recurrence